Inclusion Criteria:

- patients diagnosed as malignant lymphoma

- patients who were refractory to anthracycline or anthraquinone containing
chemotherapy

- patients who are going to receive ESHAP or CHASE treatment regimen

- ECOG performance status =< 2

- patients who have appropriate bone marrow, hepatic and renal functions

- written informed consent

Exclusion Criteria:

- double cancer

- history of bone marrow transplantation or PBSCT

- more than 2 prior chemotherapy regimens

- primary hematologic disease such as myelodysplastic syndrome

- previous radiotherapy within 4 weeks of enrollment

- woman of childbearing potential who were either pregnant, breast feeding

- patients who participated in other clinical trials within the last 4 weeks of
enrollment